Per 2 g/250 mg inj Piperacillin Na 2 g, tazobactam Na 250 mg. Per 4 g/500 mg inj Piperacillin Na 4 g, tazobactam Na 500 mg
Indications/Uses
Moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam-susceptible, β-lactamase producing strains of E. coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus in appendicitis (complicated by rupture or abscess) & peritonitis; Staph aureus in uncomplicated & complicated skin & skin structure infections, including cellulitis, cutaneous abscesses & ischemic/diabetic foot infections; E. coli in postpartum endometritis or pelvic inflammatory disease; H. influenzae in community-acquired pneumonia (moderate severity only); Staph aureus in nosocomial pneumonia (moderate to severe).
IV over 30 min. CrCl >40-90 mL/min 12 g/1.5 g/day in divided doses every 6 hr, 20-40 mL/min 8 g/1 g/day in divided doses every 6 hr, <20 mL/min 6 g/750 mg/day in divided doses every 8 hr. Hemodialysis Max: 2 g/250 mg every 8 hr followed by 750 mg piperacillin & tazobactam Na each dialysis period.
Serious anaphylactic reactions. Discontinue therapy if bleeding manifestation occurs. Neuromuscular excitability or convulsions (high doses). Patients requiring restricted salt intake. Perform periodic electrolyte determinations in patients w/ low K reserves. Hypokalemia in patients who have potentially low K reserves & are receiving cytotoxic therapy or diuretics. Renal insufficiency. Lactation. Childn.
Substantial inactivation of aminoglycosides. Prolonged t½ w/ probenecid. May affect blood coagulation system or thrombocyte function w/ heparin or oral anticoagulants. Prolonged neuromuscular blockade of vecuronium.
J01CR05 - piperacillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.
Sign Out
